We demonstrated that among ATRX-deficient cell models, the presence of the IDH1 mutation has negligible impact on proliferation; however, upon intracranial implantation, mutant IDH1 significantly increases tumor aggressiveness, as indicated through a shorter survival and greater tumor penetrance. Here, IDH1 is linked to neoplasm.